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ITAREPS presents a mobile phone-based telemedicine solution for weekly remote patient monitoring and disease management in
schizophrenia and psychotic disorders in general. The programme provides health professionals with home telemonitoring via a PC-to-
phone SMSplatform that identifies prodromal symptomsof relapse, to enable early intervention and prevent unnecessary hospitalizations.
Its web-based interface offers the authorized physician a longitudinal analysis of the dynamics and development of possible prodromes.
This work presents preliminary findings from a one-year mirror-design follow-up evaluation of the programme's clinical
effectiveness in 45 patients with psychotic illness. There was a statistically significant 60% decrease in the number of hospitalizations
during the mean 283.3±111.9 days of participation in the ITAREPS, compared to the same time period before the ITAREPS entry
(sign test, pb0.004). Variables significantly influencing the number of hospitalizations after the ITAREPS entry (medication
compliance along with factors intrinsic to the ITAREPS, i.e. adherence to the programme and involvement of a family member)
suggest a critical role of the programme in controlling the number of relapses and subsequent hospitalizations in psychosis.
© 2007 Elsevier B.V. All rights reserved.Keywords: Psychotic disorders; Schizophrenia; Relapse prevention; Hospitalizations1. Introduction
Schizophrenia is a major psychotic disorder that has
devastating effects on the lives of patients and their
caregivers.⁎ Corresponding author. Prague Psychiatric Center, Ústavní 191 181 03
Prague 8,CzechRepublic. Tel.: +42026600 3390; fax: +4202 66003366.
E-mail address: spaniel@pcp.lf3.cuni.cz (F. Španiel).
0920-9964/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.schres.2007.09.005The illness is accompanied by high rate of relapses and
readmissions. An overview of studies investigating long
term outcomes has shown that people with schizophrenia
have a one-year relapse rate of 15 to 35%, rising to 80% at
five years after the onset of first-episode, despite
maintenancemedication (Robinson et al., 1999). Achieve-
ment of full remission becomes less likely after each
relapse (Wiersma et al., 1998). In addition, an increased
number of relapses positively correlate with subsequent
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with schizophrenia (Lieberman et al., 1996; Shepherd
et al., 1989). Needless to say, these patients as well as their
caregivers experience extremely high levels of burden
related to the dramatic consequences of relapse and
hospitalization.
Studies published so far suggest that the prediction of
relapse appears to be an achievable goal for a substantial
proportion of patients with schizophrenia. The successful
prediction of relapse using new technologies e.g. tele-
medicine capabilitieswillmost likely require a combination
of components built into an integrated programme. These
components may include monitoring of non-specific and
specific prodromal symptoms, frequent assessments and an
involvement of both patients and caregivers (Fitzgerald,
2001). Crisis interventions such as increasing the dose of
antipsychotic medication, based on early detection within a
relapse prevention programme, may reduce relapse and
readmission rates compared to a treatment-as-usual group.
Timely review of patient mental status with close to real-
time feedback has been shown as a critical success factor in
the management of psychosis (Herz et al., 2000).
The future wide availability of high bandwidth public
wireless networks will give rise to newmobile health care
(or M-Health) services. These approaches allow for
home-based telemedicine ensuring the direct and prompt
communication between the clinician and the patient or
their caregiver.
The ITAREPS project (Information Technology
Aided Relapse Prevention Programme in Schizophrenia)
developed at the Prague Psychiatric Centre represents aTable 1
Early warning sings questionnaire, patient and family member version
Item
no.
EWSQ 10 Patient Version
1 Has your sleep worsened since the last evaluation?
2 Has your appetite decreased since the last evaluation?
3 Has your concentration, e.g., ability to read or watch TV, worsen
evaluation?
4 Have you experienced fear, suspiciousness, or other uneasy feelings w
other people since the last evaluation?
5 Have you experienced increased restlessness, agitation, or irritabil
evaluation?
6 Have you noticed that something unusual or strange is happening arou
last evaluation?
7 Have you experienced loss of energy or interest since the last evalua
8 Has your capability to cope with everyday problems worsened since th
9 Have you experienced hearing other people's voices even when nob
since the last evaluation?
10 Have you noticed any other of your individual early warning sig
evaluation?step towards a highly customizable prodromal signs
monitoring M-Health service platform.
1.1. The ITAREPS programme design
Participants enrolled in the ITAREPS programme (the
patient and her/his family member) were instructed to
complete a 10-item Early Warning Signs Questionnaire
(EWSQ) by a Short Message Service (SMS) request sent
weekly (on Thursdays) by an automated system to their
mobile phones. Attendance of a family member at the
ITRAEPS was highly recommended, albeit optional.
There were two versions of EWSQ, one for patients
(EWSQ-10P) and the other for their family members
(EWSQ-10FM). Full reporting on psychometric properties
of EWSQ has been published elsewhere (Spaniel et al.,
2007).
Nine of the EWSQ items covered the most common
early non-specific warning sings of the relapse. The
tenth item instructed patients and carers to list three
specific symptoms which had individually preceded
previous relapse or relapses in the given patient and
which were not included under items 1–9 (Table 1). In
case of more than one specific symptom occurrence, the
most pronounced sign was selected and scored under
item 10.
The EWSQ was designed to detect proportional
worsening (or a new onset) of symptoms compared to the
baseline (the previous week's completed questionnaire).
Each item score ranged from 0 (no worsening or
improvement of symptoms) to 4 (extreme worsening).EWSQ 10 Family Member Version
Change of the sleep pattern.
Marked behavioral changes.
ed since the last Social withdrawal.
hile being around Deterioration in daily activities and functioning.
ity since the last Deterioration in personal hygiene.
nd you since the Loss of initiative, motivation.
tion? Eccentric thought content, marked preoccupation
with strange ideas.
e last evaluation? Marked poverty of speech and content of thoughts.
ody was around Irritability, restlessness, agitation, aggressivity
ns since the last Have you noticed any other individual early
warning signs since the last evaluation?
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Individual EWSQ scores were sent by participants back to
the ITAREPS as a SMS message, presented as a string of
ten digits (i.e. 0001202001). The information was then
processed automatically. If the total score (and/or given
score in prepsychotic sub items of the EWSQ) exceeded a
given score threshold, an immediate ALERTwas declared
and the psychiatrist was notified of this by an e-mail
message.
The e-mailALERTmessage contained the code number
of the patient and an Early Intervention Algorithm (EIA).
The EIAwas a key factor allowing for early crisis interven-
tion. It consisted of five consecutive steps in which
immediate phone contact with the patient and prompt
evaluation of his/her current status was recommended.
The presence of early warning signs warranted an
immediate 20% increase from baseline maintenance dose
of antipsychotic within the next 24 h. The effectiveness of
this particular intervention has been confirmed previously
(Herz et al., 2000). To achieve the most appropriate 20%
fractional dose increase, splitting or dividing of the tablets
was to be done in the most suitable way according the
relevant antipsychotic's Product Information. The fifth
item of EIA emphasizes the importance of doctor–patient
face-to-face contacts during the treatment, pointing on the
fact that the program is not intended to reduce the number
of visits.
Once an ALERTwas declared, it continued for the next
3 week ALERT PERIOD, providing that the following 6
consecutive EWSQ scores showed no worsening of
symptoms. If so, the ALERT PERIOD was withdrawn
and the event announced to physician via e-mail alongwith
recommendation concerning subsequent tapering down the
medication to the pre-ALERT doses. During the ALERT
PERIOD, participants were to return questionnaires twice-
weekly upon SMS request (on Thursdays and Mondays).
In addition to that, more conservative score thresh-
olds were adopted. If EWSQ scores exceeded those
modified thresholds anytime during the ALERT PERI-
OD, an ALERT EMERGENCY was announced via e-
mail. In such a case the ALERT PERIOD was extended
for a further 3 weeks after each ALERT EMERGENCY
message.
Admissions to the hospital and discharge dates were
announced to the system by either and/or both patient
and family member by SMS message. In order to record
the event in the system, SMS had to follow a predefined
form. This information was automatically integrated
into line graphs accessible to clinicians. Information
about hospital admissions were subsequently confirmed
by the outpatient psychiatrist for the purpose of this
clinical evaluation.The patient data entering process was operated
exclusively on the internet using standard browsers. In
order to access the ITAREPS (www.itareps.com), partic-
ipating psychiatrists needed a username and a password.
Subsequently, his/her personal page was created in which
his/her patients were registered and assigned a specific
code number. The subject number and patient initialswere
recorded on a patient assignment log, which was kept
exclusively by the outpatient psychiatrist.
During each personal web page visit, the physician
could easily check the current medical status of his/her
patient. Longitudinal score values (both from the patient
and his/her carer) were available in a graphic form (line
graphs) and in a detailed written description which was
converted from the completed questionnaires returned
as SMS messages from patient and his/her carer. In this
way the psychiatrist could easily review the dynamics
and development of possible prodromes.
All stored data contained no patient identifiers. The data
were rendered unreadable to unauthorized persons. Data
processing and security measures addressed all known
security vulnerabilities including encryption of transmis-
sion and storage of information across the internet.
No specific training has been provided for ITAREPS
participants. According to the clinical experience with
ITAREPS program, ITAREPS User Manual distributed
to the program participants provided a firm basis for
appropriate management and system operation.
2. Methods
2.1. Subjects
A total of 45 patients and 39 family members were
enrolled in the one-year, longitudinal, mirror-design
evaluation of the ITAREPS clinical effectiveness since
its implementation in clinical practice in the Czech
Republic in September 2005. These subjects were
recruited by their psychiatrists through 14 outpatient
mental health facilities in the Czech Republic. Direct
advertising in Czech peer-reviewed journal Psychiatrie
was used for the purpose of out-patient facilities
recruitment. No financial or other incentives were given
to any participant to take part in this clinical evaluation.
Patients fulfilled ICD-10 criteria for diagnosis of
schizophrenia, schizoaffective disorder, or acute poly-
morphic psychotic disorder with or without symptoms of
schizophrenia, and were aged between 18 and 65 (Table 2).
Mean illness duration (time since occurrence of the first
psychotic symptoms) was 6.9 (SD 4.8) years in the
participants, resulting in 134 hospitalizations during a total
of 256 patient/years. Thus, cumulative hospitalization
Table 2
The demographic and clinical characteristics of the patients
Mean (SD)
Age Male N=27 (60%) 31.3 (7.6) years
Female N=18 (40%) 29.6 (5.8) years
CGI 2.6 (1.2)
N
Diagnosis Schizophrenia 29 (64.4%)
Schizoaffective disorder 11 (24.4%)
Acute polymorphic psychotic disorder with schizophrenia symptoms 4 (8.9%)
Acute polymorphic psychotic disorder without schizophrenia symptoms 1 (2.3 %)
Antipsychotic medication No 22 (48.8%)
Yes Atypical 19 (42.2%)
Classical 4 (9%)
315F. Španiel et al. / Schizophrenia Research 98 (2008) 312–317incidence in our patient groupwas 0.51 patient/years before
the ITAREPS entry.
Because this follow-up used only clinical information
without specific patient identifiers and the procedures
required no deviation from standard clinical practice,
informed consent was not obtained from participants. The
protocol of ITAREPS programme was approved by the
Ethics Committee of the Prague Psychiatric Center.
2.2. Measures
The following baseline measurements were obtained
from outpatient psychiatrists: demographic data; diagnosis;
illness history; CGI and current medication. Compliance
was evaluated by therapists using a questionnaire with a 5-
point scale (1=always and 5=never taking antipsychoticTable 3
Relationship of patient variables to hospitalization status after the ITAREPS
Variable Non-hospitalized during
ITAREPS (n=38)
Median Minimum–maximum
CGI 2.0 1–5
Illness duration (days) 2178.5 51–3910
No. of hospitalizations before ITAREPS 2.0 0–13
Medication compliance 1.5 1–3
No. of Alert states 0.0 0–26
No. of days in ITAREPS 291.0 5–565
N
Medicated/unmedicated 19/19
Inclusion of a family member Yes/No 35/3
Patient cooperation Yes/No d 32/6
Family member cooperation Yes/No d 21/17
a Two subjects were hospitalized twice during the follow-up period.
b Statistical significance at p≤0.05, exact significance, two-sided.
c Fisher's exact test.
d Cut off point of cooperativeness defined as more or less then 30% undemedication (Herz et al., 2000)). The adherence to the
ITAREPS programme was measured as a percentage
difference (PD) between the number of messages the
patient/family member were supposed to send according to
the ITAREPS programme and the number actually sent by
both participants. Patients and family members were
divided into two groups according to PD. Subjects with a
PDof less than 30%undelivered SMSmessages containing
EWSQ scores were designated as “Cooperative” and
“Uncooperative” if they had a PD of more than 30% SMS
messages missing.
2.3. Statistics
Statistical analysis was performed using the sign test,
the Mann–WhitneyU test and the Fisher's exact test. Theentry
Hospitalized during ITAREPS
(n=7) a
Difference between non-hospitalized
and hospitalized during ITAREPS
Median Minimum–maximum Mann–Whitney U (z scores) p
3.0 1–5 −1.064 0.3
3489.0 2203–4940 −1.535 0.13
6.0 1–15 −1.558 0.12
2.0 1–5 −1.969 0.04 b
0.0 0–1 −0.538 0.64
300.0 76–412 −0.047 0.97
N p c
4/3 0.69
4/3 0.05 b
3/4 0.03 b
1/6 0.09
livered SMS messages.
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exact significance, two-sided to have adequate power to
detect differences with the small number of subjects.
3. Results
In total 1540 EWSQs were completed and returned
as a SMS message by patients along with 1020 EWSQs
from family members during a total follow-up period of
34.7 patient/years.
The ITAREPS system announced the onset of early
warning sings in 88 cases based on EWSQ scores sent
by patients and in 47 cases based on family members'
reports, during the follow-up period.
The overall patient drop-out rate during the evalua-
tion period was 10%. The drop-out was defined as any
discontinuation of participation in ITAREPS programme
for more than 10 weeks.
There were 9 hospitalizations in the 45 patients
participating in the ITAREPS programme (Table 3) for a
mean of 283.3±111.9 days follow-up, compared with 27
hospitalizations during the same length of time before
entering the programme, resulting in a statistically
significant 60% reduction in the number of hospitaliza-
tions during ITAREPS programme participation (sign
test, pb0.004). There was 100% decrease in the number
of hospitalizations (from 13 to 0) in highly cooperative
patients (N=21, 47%, family member included, more
than 70% SMSs returned by both participants) during the
follow-up. Those subjects showed cumulative hospital-
ization incidence 0.42 patient/year before the ITAREPS
entry.
In a second step, Mann–Whitney or Fisher's exact tests
were performed to search for variables influencing the
number of hospitalizations after ITAREPS enrolment
(Table 2). No significant differences between hospitalized
and non-hospitalized patients in the ITAREPS programme
were found regarding the duration of illness, number of
hospitalizations before entering ITAREPS, CGI ratings
during initial visit, number of ALERT states during
ITAREPS, medication status (on or off antipsychotic
medication at the entry of the ITAREPS programme) or
duration of the ITAREPS programme participation.
However, univariate comparisons showed that non-
hospitalized patients were significantly more compliant
with their medication, more adherent to the ITAREPS
programme and had a family member significantly more
frequently involved in the programmecompared to subjects
hospitalized after ITAREPS entry. A similar but non-
significant trend related to higher familymember adherence
to the ITAREPS programmewas found in non-hospitalized
compared to hospitalized patients.4. Discussion
The prevention of relapse and readmission has high
priority in the treatment of patients with a psychotic
disorder. There is an urgent need to develop effective
relapse prevention programmes that are applicable in
routine clinical practice.
The use of telemedicine capabilities to monitor
chronically ill patients is becoming more clinically
relevant and economically cost effective.
The novel M-health management package, ITAREPS,
bymeans of a simple, interactive communication based on
user–server interactivity between healthcare professional
and project participants, can timely report prodromal
symptoms of relapse and promote appropriate measures
that can be taken for early pharmacological intervention.
This one-year mirror-design follow-up was carried out
to evaluate the impact on outcome of early intervention
enabled by the ITAREPS system in 45 patients with
psychotic illness. Significantly fewer hospitalizations
were shown in patients enrolled in the ITAREPS
programme compared to the follow-up period before the
programme entry. Among several variables that were
considered to be potentially associated with the rate of
hospitalizations after ITAREPS entry, only medication
compliance, adherence to the ITAREPS programme and
involvement of a family member in the project showed
statistical significance. Those preliminary findings sug-
gest that the parameters intrinsic to the ITAREPS
programme, along with compliance, as a crucial factor
in project efficiency resulted in a reduction of the number
of relapses and subsequent hospitalizations in psychosis.
The results of this pilot clinical evaluation must be
interpreted in light of its methodological limitations
including absence of a control group and relatively small
numbers of patients.
In addition, although a specific procedure was
recommended according to Early intervention algorithm
(EIA), the exact nature of the intervention during the
Alert states could not be documented in this clinical
evaluation. This is of particular importance in medica-
tion-free subjects (n=22, 49%) in which antipsychotic
readministration corresponds EIA during the ALERT
state.
Therefore, a prospective, double-blind, randomized
trial with the ITAREPS programme is warranted to
confirm our preliminary findings.
5. Conclusions
The ITAREPS programme presents a novel approach
towards relapse prevention which according to our
317F. Španiel et al. / Schizophrenia Research 98 (2008) 312–317knowledge has not been used before. The programme
offers affordable solution to face the challenges of
frequent rehospitalizations and relapses in patients with
schizophrenia and psychotic disorders in general.
Besides this primary effect, one of the main goals of
the program is implementing continuous quality im-
provement in the doctor–patient relationship resulting in
the strengthening and positive interference with the
rapport between physician and patient. Furthermore,
ITAREPS user-friendly, web-based data capture system
enables international large-scale naturalistic studies to
be conducted, aimed at the evaluation of long-term
outcomes, dynamic fluctuations of the course of
psychotic illness and the rate of relapses related to the
particular antipsychotic medication.Role of funding source
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